Ucello Therapeutics Company

Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Technology: CAR-T
Industry: Private
Headquarters: Chengdu, Sichuan, China
Founded Date: 2020-12-01
Funding Status: Early Stage Venture
Investors Number: 5
Total Funding: 25000000
Estimated Revenue: $10M to $50M
Last Funding Date: 2022-02-10
Last Funding Type: Series A

Visit Website
Register and Claim Ownership